Search Results 21-30 of 17619 for Thromboembolism
A Study to Evaluate the Effectiveness and Safety of Rivaroxaban as Prophylaxis Treatment for Venous Thromboembolism (VTE) in Ambulatory Cancer Patients.
This study aims to prevent the deaths and suffering associated with venous thromboembolism and bleeding by identifying the individual person at high risk of ...
... thromboembolism. These trials include the Apixaban and Dalteparin in Active Malignancy-Associated Venous Thromboembolism (ADAM VTE), CAPRINI and EVE trials.
... thromboembolism events and related death after hospital discharge in high-risk, medically ill patients. Participation eligibility. Participant eligibility ...
Almost one-half million people suffer venous thromboembolism annually in the United States, and one-third die from this disease. Massive bleeding from ...
About this study. The purpose of this registry will be to promote a greater understanding of the prevalence, pathophysiology, evaluation, and treatment of ...
Venous thromboembolism. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health-topics/venous-thromboembolism. Accessed Jan. 14, 2022 ...
... thromboembolism in the 3 months following deep vein thrombosis diagnosis in hospitalized malignant hematology patients, based on anticoagulant use and ...
Management of venous thromboembolism, including deep vein thrombosis (DVT) ... thromboembolic pulmonary hypertension (CTEPH), chronic thromboembolic ...
Her research interests include antiphospholipid syndrome, venous thromboembolism prevention and treatment, and diagnostics of vascular diseases. Her ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!